Impressive Preclinical Bisantrene Breast Cancer Results
Filed with ASX · · 7 pages · English
Earlier from Racura Oncology
- Prof Borje S Andersson appointed Chief Medical Officer
- Race leadership team strengthened
- Strategic investors make further $1.5m investment in Race
- A$3m strategic investment from prominent biotech investors
- Extension of time to repay loan through share buy-back
Later from Racura Oncology
- Race AGM presentations and strategic update
- Race receives $387k R&D tax incentive refund
- Compelling Preclinical Breast Cancer Results
- S&P DJI Announces March 2021 Quarterly Rebalance
- Race Initiates FTO Melanoma Preclinical Study
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology